Independent marketing instead of out-licensing? Panel discussion at Bio Europe Spring
In recent years, the number of pharmaceutical companies that only commercialize a single drug has risen sharply. This is because more and more biotech companies are deciding not to out-license the drug they have developed, but to bring it onto the market themselves. What are the reasons for this increase? Why are biotech start-ups deciding against out-licensing? Is independent commercialization economically successful in the long term? These questions will be the focus of a panel discussion organized by the IGES Group at the BIO-Europe Spring convention on 18 March 2025 at 10.00am. Bio Europe Spring is one of the largest life sciences conventions of its kind in Europe.
In the European Union, the number of companies marketing a single pharmaceutical product has risen from four in 2014 to 33 in 2024, IGES analyses show. Arguments for and against independent marketing instead of out-licensing are the focus of the panel. Under the moderation of Dr Tilo Mandry (Lead International Liaison Manager at the IGES Institute), Thomas Ballotti (Scientific Officer, European Medicines Agency), Delphine Bourdon (Head of International Finance, Blueprint Medicines) and Daniël Ghyssels (VP Commercial Europe, Immunocore) will discuss.
The companies Blueprint Medicines and Immunocore are ‘single-product companies’ that will share their experiences with the panel. Thomas Ballotti is responsible at the EMA for advising and supporting small and medium-sized companies in the EU authorization procedure. These are often single-product companies that are regularly unfamiliar with the EU authorization procedure and therefore face particular challenges.
BIO-Europe Spring 2025 will take place from 17 to 19 March in Milan. Around 3,700 visitors from more than 2,000 companies from the field of innovative biotech pharmaceuticals are expected to attend. The IGES Group is taking part in the congress with experts from three European countries. The aim is to enter into dialogue with researchers, companies and associations on international market access and reimbursement strategies for medical innovations.
IGES Italy Pharma Consulting will be on site for the first time as a new company of the IGES Group. Founded in 2025, the company specializes in strategic and health economic consulting services for developers and manufacturers of pharmaceuticals who intend to launch products on the Italian market.
The IGES Group offers a broad range of research and consulting services for global developers of pharmaceuticals, medical devices and digital health applications. The services support almost all phases of the product life cycle management of new inventions in Europe.
Panel Discussion
A work of art: Success as a first-time launcher in Europe
Dienstag, 18. März 2025, 10:00 - 10:45 (MEZ, UTC/GMT +2 Stunden) Exhibit Hall Stage
Location: Allianz MiCo, Central Building, Entrance via Gate 5
Corner of Viale Teodorico & Viale Lodovico Scarampo
20149 Mailan, Italien
Panelists
Thomas Ballotti (Scientific Officer, European Medicines Agency)
Delphine Bourdon (VP, Head of International Finance, Blueprint Medicines)
Moderator: Dr. Tilo Mandry (Lead International Liaison Manager, IGES)
Only necessary cookies are used on our website. We also carry out anonymous visitor measurement using the Matomo tool. For this purpose, the log data of the web server and the shortened IP address are analysed. It is not possible to draw conclusions about your person. Information on the processing of your data on our website can be found in our privacy policy.
Contact